文献速递肿瘤 PET/CT神经核医学

68Ga-DOTATOC PET/CT 在转移性神经内分泌肿瘤患者中对未知原发灶的定位

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.
PubMed 文献 · J Nucl Med · 2017-02-02

该单中心前瞻性研究纳入40例转移性神经内分泌肿瘤且原发灶未知的患者,行68Ga-DOTATOC PET/CT 寻找原发灶。原发灶真阳性率38%、假阳性率7%、假阴性率50%、未确认率5%。作者认为68Ga-DOTATOC PET/CT 是定位转移性NET未知原发灶的有效方法。

要点

  • 40例转移性NET未知原发灶患者行68Ga-DOTATOC PET/CT,原发灶真阳性率38%。
  • 原发灶假阳性率7%、假阴性率50%、未确认率5%。
  • 作者认为该显像对定位转移性NET未知原发灶有效。

核心结论

  • 作者认为68Ga-DOTATOC PET/CT 是定位转移性神经内分泌肿瘤患者未知原发灶的有效方法。

研究设计与样本

  • 单中心前瞻性研究,纳入40例转移性神经内分泌肿瘤且原发灶未知的患者,均行68Ga-DOTATOC PET/CT。
  • 原发灶阳性部位经组织学或随访影像证实者判为真阳性,未找到对应原发灶者判为假阳性,原发灶阴性扫描判为假阴性,提示原发灶但无组织学且影像随访不能证实者判为未确认。

主要发现

  • 未知原发灶的真阳性率为38%、假阳性率为7%、假阴性率为50%、未确认率为5%。

关键数值与推荐

  • 原发灶真阳性、假阳性、假阴性、未确认率分别为38%、7%、50%、5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Localization of the site of the unknown primary tumor is critical for surgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases. Methods: Forty patients with metastatic NET and unknown primary site underwent 68Ga-DOTATOC PET/CT in a single-site prospective study. The 68Ga-DOTATOC PET/CT was considered true-positive if the positive primary site was confirmed by histology or follow-up imaging. The scan was considered false-positive if no primary lesion was found corresponding to the 68Ga-DOTATOC-positive site. All negative scans for primary tumor were considered false-negative. A scan was classified unconfirmed if 68Ga-DOTATOC PET/CT suggested a primary, however, no histology was obtained and imaging follow-up was not confirmatory. Results: The true-positive, false-positive, false-negative, and unconfirmed rates for unknown primary tumor were 38%, 7%, 50%, and 5%, respectively. Conclusion:68Ga-DOTATOC PET/CT is an effective modality in the localization of unknown primary in patients with metastatic NET.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Menda Y, O'Dorisio TM, Howe JR, et al. Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. J Nucl Med. 2017. PMID: 28153957. doi:10.2967/jnumed.116.180984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。